Transcript Examples of CAN-BD - aktiv

CAN-BD® Experience
Vaccines
Live attenuated measles
Live attenuated influenza
Hepatitis B surface antigen
Antibodies
PRIMATIZED® anti-CD4
Human IgG
Anti-human lambda light chain
Proteins and
Peptides
α1-antitrypsin
Trypsinogen
Lactate dehydrogenase
Lysozyme
Insulin
Alkaline phosphatase
Antibiotics
Moxifloxacin
Tobramycin
Amoxycillin
Doxycycline
Cefazolin
Ciprofloxacin
Amikacin
Capreomycin
Rifampin
Antivirals
siRNA
In Vivo Tests of Live Virus Vaccine
CAN-BD-produced powders have also proven successful in vivo.
We have shown dose-dependent deposition and replication of
live-virus measles powder in the lungs of cotton rats during tests
by Dr. Kevin Kisich at the National Jewish Medical Research
Center.
a
Buffers
Surfactants
Amino acids
Metal chelating agents
50,000
25,000
0
0
5
10
15
20
25
Day after inoculation
30
Copies of mRNA nucleoprotein in
lungs
75,000
Copes of nucleoprotein in lungs
Formulation
Components
Sucrose
Trehalose
Mannitol
Lactose
Myo-inositol
Sorbitol
Heparin
Copes of nucleoprotein in lungs
Carbohydrates
b
1,000,000
750,000
500,000
250,000
0.0
0
5
10
15
20
25
30
Day after inoculation
Cotton rats were vaccinated via inhalation of dry-powder measles
from the
PuffHaler
device.
RNA
extractedviafrom the
Figure 1. Viral replication vaccine
following immuni
zation
wit h dry powde
rs. Cotton
rats was
were vaccinated
lungs
at
increasing
intervals
and
assessed
for
inhalation of dry-powder measles vaccine from the Solovent (A), or Puffhaler device (B). RNA the
was number of
nucleoprotein
RNA
copies
(y
axis).
Error
bars
represent
extracted from the lungs at increasing intervals and assessed for the number of nucleoprotein RNA copiesstandard
of 4-5 ofsamples.
(y axis). Error bars representdeviation
standard deviation
4-5 samples. NOTE: device performance is not
directly comparable between A and B due to different powder characteristics used for each
immunization.
Aqueous and organic solvents